Epigenetics in Drug Discovery
Sunday April 22, 2018
3:30 pm
-
6:00 pm
Eastern Time (ET)
Room 15B
DCP
DDD
DMDD
TOX
TCP
Chair :
Joseph Jilek
University of California, Davis
Venkat Vaka
University of Mississippi Medical Center
Epigenetics is defined as the study on heritable changes in gene expression without any alterations in primary DNA sequence. Alterations in epigenetic control mechanisms lead to aberrant gene expression patterns and contribute to the pathogenesis of various diseases, including cancer, cardiovascular, and neurodegenerative diseases.The proposed symposium will introduce the topic of epigenetics and its pivotal role in drug discovery. Symposium will highlight recent advances in epigenetics research and the opportunities in leveraging epigenetic mechanisms to target-based discovery and development. Progress made in the application of the field to the development of potential therapeutics to areas beyond cancer will be discussed.
Speakers
Patrick Woster
- Medical University of South Carolina College of Pharmacy
Epigenetic Drug Discovery Beyond Cancer
Sharad Verma
- Johns Hopkins School of Medicine
Therapy Acceleration via Precision Medicine
Ai-Ming Yu
- University of California, Davis
MicroRNA Epigenetics & Therapy: Are We Using the Right Agents?
Nate Hathaway
- UNC Eshelman School of Pharmacy
Pathway Based Chemical Screen Identifies New Components of Epigenetic Gene Repression as Potential New Cancer Therapeutics
Seena Ajit
- Drexel University College of Medicine
Exosome Mediated Intercellular Communication in Pain
Gwen Lomberk
- Medical College of Wisconsin
Targeting of the Histone 3 Lysine 9 Methyltransferase Pathway in Kras-Induced Cell Growth and Pancreatic Cancer
Jia Cui
- University of Alabama-Birmingham
Crosstalk Between PTBP1 and miR-101/AGO2 on Targeting MCL1 – A Novel Post-Transcriptional Mechanism for MCL1 Expression